R&D channel feed – Endpoints News

R&D channel feed

Three papers on MDMA are retracted by medical journal, just a day after Lykos' FDA rejection

9 months ago

Pfizer touts strength of RSV vaccine in subgroup of younger immunocompromised patients

9 months ago

Amgen announces plans for new site in India to strengthen AI, data and life sciences

9 months ago

Genentech, Gilead push FDA to modernize research inspections

9 months ago

Autoimmune CAR-Ts are under the microscope after Cabaletta’s safety issue in lupus

9 months ago

Avidity CEO says it's ‘full steam ahead’ in DMD as stock rallies on Phase 1/2 win

9 months ago

FDA lifts hold on 4DMT's Fabry gene therapy

9 months ago

Infectious disease biotech undergoes makeover after lung disease trial underwhelms

9 months ago

Aldeyra to resubmit dry eye disease drug this year following positive Phase 3 data

9 months ago

Lilly’s anti-tau pill for Alzheimer’s fails in Phase 2 study

9 months ago

Apellis and Sobi land another late-stage win for rare kidney disease drug

9 months ago

Intellia’s gene editing therapy succeeds in Phase 2 genetic swelling condition study

9 months ago

TIGIT drugs take another hit as Merck stops Phase 3 lung cancer trial for futility

9 months ago

Sanofi’s Sarclisa scores in Phase 3 transplant-eligible multiple myeloma test

9 months ago

FDA grapples with its role in AI, and how to guide industry's adoption

9 months ago

Exelixis’ Cabometyx misses survival endpoint, but will still file in prostate cancer

9 months ago

Updated: Novo Nordisk yanks Wegovy filing for heart failure from FDA, will resubmit next year

9 months ago

Precigen lays off staff, pauses multiple CAR-T programs and all preclinical work and aims for $30M offering

9 months ago

Updated: FDA approves Servier’s brain cancer drug, setting up $1B payout for Agios

10 months ago

Bicycle Therapeutics focuses pipeline and streamlines leadership team

10 months ago

Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B

10 months ago

Genentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy

10 months ago

A new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’ antivirals

10 months ago

Ultimovacs’ cancer vaccine flunks again — this time in head and neck cancer

10 months ago

First page Previous page 32 33 343536 37 38 Next page Last page